Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

Clinical sensitivity of HPV assays for the detection of high grade cervical disease in cervical samples treated with glacial acetic acid.

Moore C, Duvall E, Braby E, Reid G, Docherty E, Grieve L, Cubie H, Graham C, Cuschieri K.

J Clin Virol. 2016 Jun;79:32-5. doi: 10.1016/j.jcv.2016.03.020. Epub 2016 Mar 22.

PMID:
27060653
2.

Use of thermo-coagulation as an alternative treatment modality in a 'screen-and-treat' programme of cervical screening in rural Malawi.

Campbell C, Kafwafwa S, Brown H, Walker G, Madetsa B, Deeny M, Kabota B, Morton D, Ter Haar R, Grant L, Cubie HA.

Int J Cancer. 2016 Aug 15;139(4):908-15. doi: 10.1002/ijc.30101. Epub 2016 May 4.

PMID:
27006131
3.

Use of HPV testing for cervical screening in vaccinated women--Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study.

Bhatia R, Kavanagh K, Cubie HA, Serrano I, Wennington H, Hopkins M, Pan J, Pollock KG, Palmer TJ, Cuschieri K.

Int J Cancer. 2016 Jun 15;138(12):2922-31. doi: 10.1002/ijc.30030. Epub 2016 Feb 26.

PMID:
26845632
4.

Prevalence of and Risk Factors for Anal Oncogenic Human Papillomavirus Infection Among HIV-Infected Women in France in the Combination Antiretroviral Therapy Era.

Heard I, Poizot-Martin I, Potard V, Etienney I, Crenn-Hebert C, Moore C, Touraine P, Cubie H, Costagliola D; ANRS-C017 VIHGY Study Group.

J Infect Dis. 2016 May 1;213(9):1455-61. doi: 10.1093/infdis/jiv751. Epub 2015 Dec 21.

PMID:
26690345
5.

High Prevalence of Anal Human Papillomavirus-Associated Cancer Precursors in a Contemporary Cohort of Asymptomatic HIV-Infected Women.

Heard I, Etienney I, Potard V, Poizot-Martin I, Moore C, Lesage AC, Ressiot E, Crenn-Hebert C, Fléjou JF, Cubie H, Costagliola D, Darragh TM; ANRS-C017 VIHGY Study Group.

Clin Infect Dis. 2015 May 15;60(10):1559-68. doi: 10.1093/cid/civ049. Epub 2015 Feb 2.

6.

Increased cycling cell numbers and stem cell associated proteins as potential biomarkers for high grade human papillomavirus+ve pre-neoplastic cervical disease.

Canham M, Charsou C, Stewart J, Moncur S, Hoodless L, Bhatia R, Cong D, Cubie H, Busby-Earle C, Williams A, McLoughlin V, Campbell JD, Cuschieri K, Howie S.

PLoS One. 2014 Dec 22;9(12):e115379. doi: 10.1371/journal.pone.0115379. eCollection 2014.

7.

Comparison of the performance of HPV tests in women with abnormal cytology: results of a study within the NHS cervical screening programme.

Moss SM, Bailey A, Cubie H, Denton K, Sargent A, Muir P, Vipond IB, Winder R, Kitchener H.

Cytopathology. 2015 Dec;26(6):373-80. doi: 10.1111/cyt.12210. Epub 2014 Oct 2.

PMID:
25274541
8.

Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland.

Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Cruickshank M, Palmer TJ, Nicoll S, Donaghy M.

Br J Cancer. 2014 Oct 28;111(9):1824-30. doi: 10.1038/bjc.2014.479. Epub 2014 Sep 2.

9.

Influence of HPV type on prognosis in patients diagnosed with invasive cervical cancer.

Cuschieri K, Brewster DH, Graham C, Nicoll S, Williams AR, Murray GI, Millan D, Johannessen I, Hardie A, Cubie HA.

Int J Cancer. 2014 Dec 1;135(11):2721-6. doi: 10.1002/ijc.28902. Epub 2014 Apr 29.

10.

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types.

Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Donaghy M.

Br J Cancer. 2014 May 27;110(11):2804-11. doi: 10.1038/bjc.2014.198. Epub 2014 Apr 15.

11.

Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H).

Cubie HA, Canham M, Moore C, Pedraza J, Graham C, Cuschieri K.

J Clin Pathol. 2014 Jun;67(6):458-63. doi: 10.1136/jclinpath-2013-202014. Epub 2014 Jan 16.

PMID:
24436334
12.

Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age.

Cuschieri K, Cubie H, Graham C, Rowan J, Hardie A, Horne A, Earle CB, Bailey A, Crosbie EJ, Kitchener H.

J Clin Virol. 2014 Feb;59(2):104-8. doi: 10.1016/j.jcv.2013.12.001. Epub 2013 Dec 12.

PMID:
24380720
13.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; authors of ICO Monograph Comprehensive Control of HPV Infections and Related Diseases Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Dec 31;31 Suppl 7:H1-31. doi: 10.1016/j.vaccine.2013.10.003.

PMID:
24332295
14.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Dec 30;31 Suppl 6:G1-31. doi: 10.1016/j.vaccine.2013.10.002. Review.

PMID:
24331817
15.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; Authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Nov 22;31 Suppl 8:I1-31. doi: 10.1016/j.vaccine.2013.07.026. Review.

16.

Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact.

Kavanagh K, Sinka K, Cuschieri K, Love J, Potts A, Pollock KG, Cubie H, Donaghy M, Robertson C.

BMC Infect Dis. 2013 Nov 5;13:519. doi: 10.1186/1471-2334-13-519.

17.

Assessing the detection of human papillomavirus late mRNA in liquid base cytology samples for risk stratification of cervical disease.

Chambers G, Millan D, Cuschieri K, Cubie HA, Graham SV.

J Med Virol. 2014 Apr;86(4):627-33. doi: 10.1002/jmv.23793. Epub 2013 Oct 19.

18.

Cervical cancers associated with human papillomavirus types 16, 18 and 45 are diagnosed in younger women than cancers associated with other types: a cross-sectional observational study in Wales and Scotland (UK).

Powell N, Cuschieri K, Cubie H, Hibbitts S, Rosillon D, De Souza SC, Molijn A, Quint W, Holl K, Fiander A.

J Clin Virol. 2013 Nov;58(3):571-4. doi: 10.1016/j.jcv.2013.08.020. Epub 2013 Aug 30.

PMID:
24051043
19.

Understanding HPV tests and their appropriate applications.

Cubie HA, Cuschieri K.

Cytopathology. 2013 Oct;24(5):289-308. doi: 10.1111/cyt.12083. Epub 2013 Sep 2. Review.

PMID:
23998275
20.

Diseases associated with human papillomavirus infection.

Cubie HA.

Virology. 2013 Oct;445(1-2):21-34. doi: 10.1016/j.virol.2013.06.007. Epub 2013 Aug 9.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk